The Role of Albumin/Globulin Ratio in Discharged COVID-19 Patients with Re-Positive Nucleic Acid Detection
Received 1 July 2020
Accepted for publication 12 September 2020
Published 12 October 2020 Volume 2020:13 Pages 713—717
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Ning Quan
Yu Hao,1,* Ting Li,1,2,* Chanfan Zheng,2 Shengwei Jin1
1Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2Clinical Research Unit, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shengwei Jin Email [email protected]
Novel coronavirus disease (COVID-19) pandemic is becoming a threat of global public health. Up to Aug 31, 2020, 182 countries and territories have reported a cumulative total of 24,854,140 COVID-19 cases; 838,924 of them have died (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports). Recent data noticed that SARS-CoV-2 RNA test results of the recovered COVID-19 patients returned positive, termed “re-positive” phenomenon.1,2 However, the clinical characteristics and the immune biomarkers of “re-positive” COVID-19 patients are still far from being fully understood. We therefore conducted this retrospective study to clarify the clinical features and possible risk predictors of “re-positive” in discharged COVID-19 patients.
From Jan 17, 2020, to Mar 16, 2020, 503 COVID-19 patients were discharged from eight hospitals in Wenzhou City, Zhejiang Province, China. Patients were discharged if they met the criteria based on the National Health Commission of the People’s Republic of China, the diagnosis and treatment plan for the novel coronavirus disease (7th). We followed up 369 COVID-19 convalescent patients. The nasopharyngeal and cloacal swab samples were both detected for SARS-CoV-2 nucleic acid every week in one-month follow-up after discharge. Among them, 23 discharged patients identified positive results again. We collected and analyzed the demographic, clinical characteristics, and critical laboratory findings of 369 discharged COVID-19 patients on the first admission. The demo-graphics and clinical characteristics between COVID-19 patients with and without “re-positive” are presented in Table 1. Recent studies found that young COVID-19 patients are more likely to appear in the “re-positive” phenomenon.3 As shown in Table 1, there was no significant difference in age and gender distribution. There were no significant differences in initial clinical symptoms and laboratory findings at baseline between Re-positive and Non-re-positive group.
Table 1 Characteristics at Baseline in COVID-19 Patients with and without Re-Positive Findings
Subsequently, we did correlation analysis to demonstrate whether specific laboratory indicators are related to the critical period of these “re-positive” patients’ disease processes (Supplemental Table). These patients had experienced an average of 22 days (IQR: 16–29.5) of hospital stay, while 7 days (IQR: 7–13) of the duration from hospital discharge to positive again. Meanwhile, the mean duration of antivirus treatment was 12 days (IQR: 9–17). The average period from onset of symptoms to the end of antivirus treatment was 16 days (IQR: 11.25–22.75). Overall, there were no apparent differences in the two age groups. As shown in Figure 1A, correlation analysis indicated that there was a significant positive correlation existing between AGR at first admission and the period from hospital discharge to positive again in these 23 patients (r=0.49, p=0.0343). We also found that AGR at first admission was markedly positively correlated (r=0.72, p=0.00048) with the duration from last negative to positive again (Figure 1B).
Figure 1 Correlation analysis for albumin/globulin ratio (AGR) and the period from hospital discharge to positive again (A) or the duration from last negative to positive again (B).
In summary, these 23 “re-positive” patients showed several features as a mild symptom, which is consistent with a previous study.3 However, there were no more cases in the lower age group in our study. This may be related to the sample size and age stratification of the present study. Hypertension, markedly common in older patients, maybe a host risk factor for severe SARS-CoV-2.4 AGR combines the nutritional as well as the inflammatory status in one measure, it may be a good indicator reflecting these two factors.5 It can be regarded as an index for predicting the prognosis of AECOPD and other inflammatory diseases.6 Recent studies indicated that a low AGR may respect a susceptible state to infection.5,6 We suggested that “re-positive” patients may not sufficiently apparent the virus. Our results indicated that AGR may potentially have a predictive effect in “re-positive” discharged COVID-19 patients. Further definitive largescale clinical studies are feasible and needed.
Ethics Approval and Consent to Participate
The study complied with the declaration of Helsinki and was approved by the Institutional Review Board (IRB) of Wenzhou Medical University (No.2020-004). Informed consent was obtained from all participants.
We acknowledge all health care workers from the eight hospitals who involved in the diagnosis and treatment of the COVID-19 patients in Wenzhou.
This work was supported by: National Major Scientific and Technological Special Project of china for: Significant New Drugs Development(2020ZX09201002); Wenzhou Science and technology key problem program [ZY2020001]; The critical research and development program of Zhejiang Province [2019C03011]; The research was designed, conducted, analyzed, and interpreted by the authors entirely independently of the funding sources.
All authors report no potential conflicts of interest for this work.
1. Lan L, Xu D, Ye G, et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA. 2020;323(15):1502. doi:10.1001/jama.2020.2783
2. Li J, Long X, Fang X, et al. SARS-CoV-2 positivity in a discharged COVID-19 patient: a case report. Clin Microbiol Infect. 2020;26(8):1115–1117. doi:10.1016/j.cmi.2020.04.032
3. Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. PCR assays turned positive in 25 discharged COVID-19 patients. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa398
4. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(1):108. doi:10.1186/s13054-020-2833-7
5. Xun Y, Yang Y, Yu X, Li C, Lu J, Wang S. A preoperative nomogram for sepsis in percutaneous nephrolithotomy treating solitary, unilateral and proximal ureteral stones. PeerJ. 2020;8:e9435. doi:10.7717/peerj.9435
6. Qin J, Qin Y, Wu Y, et al. Application of albumin/globulin ratio in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. J Thorac Dis. 2018;10(8):4923–4930. doi:10.21037/jtd.2018.07.47
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]